Showing 3071-3080 of 5154 results for "".
- Arcutis, Huadong Announce Strategic Collab and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asiahttps://practicaldermatology.com/news/arcutis-huadong-announce-strategic-collab-and-licensing-agreement-for-topical-roflumilast-in-greater-china-and-southeast-asia/2461921/Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co. have entered into a strategic c
- Bristol Myers Squibb’s New Sotyktu Campaign Reveals the Plain Truth About Living With Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibbs-new-clear-understanding-campaign-reveals-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2461914/Bristol Myers Squibb is rolling
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi
- Revealed: Why Skin Gets 'Leathery' After Too Much Sunhttps://practicaldermatology.com/news/revealed-why-skin-gets-leathery-after-too-much-sun/2461875/When exposed to too much ultraviolet radiation, collagen fibers become more tightly packed together, according to research in the Journal of the Mechanical Behavior of Biomedical Mate
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- PathologyWatch Launches ‘Show Me Some Skin’ Campaign for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/pathologywatch-launches-show-me-some-skin-campaign-for-skin-cancer-awareness-month/2461696/
- SkinGPT Uses AI to Visualize Long-Term Skincare Benefitshttps://practicaldermatology.com/news/skin-gpt-uses-ai-to-visualize-long-term-skincare-benefits/2461670/Haut.AI is incorporating its new generative AI tech for modeling skin conditions over time. SkinGPT uses AI to create synthetic images and apply skin conditions to input image data. SkinGPT enables users to upload their photos and apply AI to
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac